Aurora Cannabis Reports Strong Q2 Growth Driven By International Medical Marijuana Sales
Aurora Cannabis Reports Strong Q2 Growth Driven By International Medical Marijuana Sales
極光大麻報告顯示,國際醫療大麻銷售推動了強勁的Q2增長。
Canadian medical marijuana giant Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB) reported its financial results Wednesday for the second quarter of fiscal 2025, showing revenue of CA$81.1 million ($58.3 million), up from CA$63.1 million in the same period last year.
加拿大醫療大麻巨頭極光大麻股份有限公司(納斯達克:ACB)(tsx:ACB)週三公佈了2025財年第二季度的財務結果,顯示營業收入爲CA$8110萬($5830萬),較去年同期的CA$6310萬有所增長。
The company attributed the 29% increase from the prior period to 41% growth in its global medical cannabis business and 21% growth in its plant propagation business, slightly offset by lower quarterly revenue in its consumer cannabis business.
公司表示,與前一時期相比增長29%,其中全球醫療大麻業務增長41%,植物繁殖業務增長21%,略有偏低的消費大麻業務季度收入。
"Our strong quarterly results demonstrate Aurora's leadership in global medical cannabis and ability to capitalize on opportunities within rapidly growing markets such as Australia, Germany, Poland...
「我們強勁的季度業績展示了極光大麻在全球醫療大麻領域的...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。